IXJ vs. RSPH: Which Healthcare ETF Is the Better Buy?
2026-07-21 17:32
•Andy Gould •The Motley Fool
•••• •••••• Axe Capital view
Healthcare ETFs: Stability or Growth on the JSE?
IXJ offers income and stability; RSPH pushes growth but with more volatility—choose based on your local appetite and risk tolerance.
South African investors looking at healthcare exposure face a familiar trade-off when comparing global ETFs IXJ and RSPH. IXJ leans on big pharma names like Johnson & Johnson and Eli Lilly, delivering a respectable yield of around 1.5% and lower volatility, which suits those who prefer predictable income and downside protection. That’s potentially interesting for conservative JSE investors seeking to balance rand risk amid USD/ZAR fluctuations. On the other hand, RSPH’s equal weighting favors smaller, growth-driven U.S. healthcare stocks like Moderna. It has outperformed over one year but with significantly higher swings, which may not suit every rand-based portfolio. Given the rand's sensitivity to global risk, exposure to RSPH could amplify currency-driven volatility. If your goal is steady dividends with less turbulence, IXJ makes more sense locally. But for those hungry for growth and able to stomach currency gyrations alongside higher stock volatility, RSPH is worth a look. If the rand suddenly strengthens or global healthcare faces sector-specific shocks, both strategies could falter. this is just my opinion and not financial advice
I would allocate conservatively to IXJ for steady income and lower volatility, keeping RSPH only for a smaller growth tilt. Watch USD/ZAR closely as moves there will impact returns markedly.
- IXJ
- RSPH
- USD/ZAR
- Rand volatility affecting returns
- Sector-specific shocks in global healthcare
6/10
IXJ and RSPH are two healthcare ETFs with different strategies: IXJ uses cap-weighted global exposure with larger pharmaceutical companies, offering higher dividends (1.47%) and lower volatility (beta 0.52), while RSPH employs equal-weighting of S&P 500 healthcare stocks, providing stronger 1-year returns (21.01% vs 18.29%) but higher risk (beta 0.81). The choice depends on investor goals—IXJ suits conservative/income-focused investors, while RSPH appeals to growth-oriented investors willing to accept volatility.
This article was originally published by The Motley Fool and has been adapted here for Axe Capital Trading News.
Publisher: The Motley Fool
Author: Andy Gould
Categories: Rates, Equities, Capital Returns, Healthcare
Tickers: IXJ, RSPH, LLY, JNJ, ABBV, MRNA
Sentiment: Positive - Offers higher dividend yield (1.47%), lower volatility (beta 0.52), greater diversification with 110 holdings, and stronger 5-year total return ($1,251 on $1,000 invested). Better suited for conservative and income-seeking investors. Demonstrates stronger 1-year performance (21.01%), provides exposure to smaller growth-oriented healthcare companies, and offers equal-weight diversification. Better for growth-focused investors willing to accept higher volatility.
Keywords: healthcare ETF, cap-weighted vs equal-weight, dividend yield, volatility, portfolio diversification, pharmaceutical exposure
Insights:
- IXJ: Positive: Offers higher dividend yield (1.47%), lower volatility (beta 0.52), greater diversification with 110 holdings, and stronger 5-year total return ($1,251 on $1,000 invested). Better suited for conservative and income-seeking investors.
- RSPH: Positive: Demonstrates stronger 1-year performance (21.01%), provides exposure to smaller growth-oriented healthcare companies, and offers equal-weight diversification. Better for growth-focused investors willing to accept higher volatility.
- LLY: Neutral: Mentioned as a major holding in IXJ (10.9%), representing established pharmaceutical company with steady cash flows and dividend history, but no specific performance commentary provided.